Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 20/20 | 1.00 |
| ▸ | HTR3A | P46098 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 8/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14734867 | 0.87 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Tert-Butyl Formate SCHEMBL28112152 | 0.86 | HTR1A (0.73) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL546684 | 0.85 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL546677 | 0.85 | HTR1A (0.77) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL547488 | 0.85 | HTR1A (0.77) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL546723 | 0.85 | HTR1A (0.78) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL547714 | 0.84 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Bromide SCHEMBL20360588 | 0.84 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27550397 | 0.81 | HTR1A (0.71) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL546962 | 0.81 | HTR1A (0.67) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127389-A1 | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors | H. LUNDBECK A/S (DK) | 2018-05-10 | — | — | US | claimed |
| EP-1436271-B1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | LUNDBECK & CO AS H (DK) | 2008-02-20 | — | — | EP | claimed |
| CN-1319958-C | Phenyl piperazine derivatives as serotonin reuptake inhibitors | LUNDBECK & CO AS H (DK) | 2007-06-06 | — | — | CN | claimed |
| US-20070060574-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2007-03-15 | — | — | US | claimed |
| US-7144884-B2 | E.g., 4-[2-(4-Methylphenoxy)- or 4-[2-(4-Methylphenylsulfanyl)-phenyl]-3,6-dihydro-2H-pyridine or piperazine or the hydrochloride or oxalate; treating depression, anxiety disorder, and obsessive compulsive disorder. | H. LUNDBECK A/S (DK) | 2006-12-05 | — | — | US | claimed |
| US-20050014740-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2005-01-20 | — | — | US | claimed |
| CN-1561336-A | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | LUNDBECK & CO AS H (DK) | 2005-01-05 | — | — | CN | claimed |
| EP-1436271-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2004-07-14 | — | — | EP | claimed |
| WO-2003029232-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | WO | claimed |
| EP-3484462-B1 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR SKIN AND/OR HAIR REPAIR | PASTEUR INSTITUT (FR) | 2022-12-14 | — | — | EP | disclosed |
| US-11344515-B2 | 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation | INSTITUT PASTEUR (FR) | 2022-05-31 | — | — | US | disclosed |
| EP-1436271-B3 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H LUNDBECK AS (DK) | 2022-04-20 | — | — | EP | disclosed |
| EP-3377051-B1 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR ENHANCING IN VIVO ENGRAFTMENT POTENTIAL | PASTEUR INSTITUT (FR) | 2022-03-30 | — | — | EP | disclosed |
| US-20210330863-A1 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR ENHANCING IN VIVO ENGRAFTMENT POTENTIAL | UNIVERSITÉ PARIS CITÉ (FR) | 2021-10-28 | — | — | US | disclosed |
| US-20060089368-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2006-04-27 | — | — | US | disclosed |
| US-20060084662-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2006-04-20 | — | — | US | disclosed |
| US-20050014740-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | H. LUNDBECK A/S (DK) | 2005-01-20 | — | — | US | disclosed |
| CN-1561336-A | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | LUNDBECK & CO AS H (DK) | 2005-01-05 | — | — | CN | disclosed |
| EP-1436271-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. Lundbeck A/S (DK) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003029232-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344515-B2 | 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation | CHRNB1, HTR1B, CHRNB2 | HTR1A 5/4885HTR3A 14/4885CYP1A2 3565/4885 |
| US-20060089368-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | TPH1, HTR5A, HTR2C | HTR1A 5/4885HTR3A 9/4885CYP1A2 309/4885 |
| US-20050014740-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | TPH1, HTR5A, HTR2C | HTR1A 5/4885HTR3A 9/4885CYP1A2 309/4885 |
| US-20180127389-A1 | Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors | TPH1, HTR5A, HTR2C | HTR1A 5/4885HTR3A 9/4885CYP1A2 309/4885 |
| US-20060084662-A1 | Phenyl-piperazine derivatives as serotonin reuptake inhibitors | TPH1, HTR5A, HTR2C | HTR1A 5/4885HTR3A 9/4885CYP1A2 309/4885 |
| US-20210330863-A1 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR ENHANCING IN VIVO ENGRAFTMENT POTENTIAL | HTR1B, HTR3B, HTR2B | HTR1A 4/4885HTR3A 7/4885CYP1A2 3146/4885 |
| US-20070060574-A1 | PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | TPH1, HTR5A, HTR2C | HTR1A 5/4885HTR3A 9/4885CYP1A2 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.